Two of Chi­na's top PD-(L)1 play­ers team up on CT­LA-4 in $200M deal

Now that the PD-(L)1 craze has (large­ly) swept through Chi­na, re­sult­ing in the ap­proval of more than a dozen drugs with more to come, two of the top do­mes­tic on­col­o­gy play­ers are team­ing up to go af­ter the oth­er check­point tar­get.

Hen­grui is li­cens­ing ex­clu­sive Chi­na rights to CStone’s CT­LA-4 in­hibitor, CS1002, in a deal worth up to $200 mil­lion, which cov­ers re­search, de­vel­op­ment, reg­is­tra­tion, man­u­fac­tur­ing and com­mer­cial­iza­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.